FDA waxay ansaxineysaa Keytruda pembrolizumab oo ah xariiqa koowaad ee difaaca jirka ee kansarka mindhicirka ee horumarsan

Daaweynta Rna Saldhigyada

Kani waa kii 9aad ee ansixinta FDA ee ay taageerto cilmi baarista Istaag Ilaa Kansarka.

FDA dhawaan ansixiyay dawada immunotherapy pembrolizumab sida daaweyn safka hore ah oo loogu talagalay bukaanada qaba noocyada qaarkood kansarka mindhicirka sare. Kani waa oggolaanshaha 9 -aad ee FDA oo ay taageerto cilmi -baarista Stand Up To Cancer® (SU2C).

Bukaannada cusub ee laga helay xasilooni-darrada microsatellite-ka sare ama metastatic-sare (MSI-H) or kansarka mindhicirka ee dayactirka aan habboonayn (dMMR) hore ayaa loo qori lahaa pembrolizumab kaliya ka dib markii la daalay daaweynta kiimoteraabiga ee caadiga ah.

FDA waxay oggolaatay pembrolizumab, oo sidoo kale lagu yaqaan magaca sumadda keytruda, sida daaweynta safka koowaad loogu talagalay MSI-H metastatic MSI-H-dMMR kansarka mindhicirka oo ku salaysan natiijooyinkii hore ee tijaabada kiliiniga wajiga III, oo qayb ahaan lagu maalgeliyey deeq SU2C ah.

"Marka la barbardhigo daaweynta dhaqameed, pembrolizumab wuxuu ka fiicnaaday waxyeelada yar ee MSI-H-dMMR colorectal bukaanka," ayuu yiri Luis A. Diaz, MD, Madaxa Qeybta Solid Tumor Oncology ee Memorial Sloan Kettering Cancer Center iyo hogaamiyaha SU2C Kooxda Riyada Midabaynta Kansarka, kaas oo sameeyay cilmi baarista. "Waxaa jira kansarro kale oo adag oo kansar ah oo ku dhaca dadka waaweyn iyo carruurta kuwaas oo leh isla cilladahan MSI-H-dMMR, sidaa darteed cilmi-baaristeena sidoo kale waxay yeelan kartaa cilado noocyada kale ee kansarka ah."

Qiyaastii 4-5% ee burooyinka kansarka ba'an ayaa leh MSI-H-dMMR biomarkers, taas oo ka dhalaneysa awood la'aanta unugyada inay hagaajiyaan khaladaadka la sameeyay intii lagu jiray howsha qeybinta unugyada waxayna u horseedi kartaa horumarin buro badan.

Daraasadu waxay ku lug laheyd 307 MSI-H-dMMR bukaanka kansarka mindhicirka ee 23 dal oo lagu daaweeyay midkood pembrolizumab ama daaweynta caadiga ah ee daaweynta kiimikada. Pembrolizumab wuxuu bartilmaameedsadaa oo xiraa borotiin la yiraahdo PD-1 kaas oo ka hortagi kara unugyada difaaca jirka ee loo yaqaan 'T cells' si looga takhaluso unugyada kansarka si wax ku ool ah.

Dr. Diaz iyo kooxdiisu waxay ogaadeen in bukaanada loo yaqaan 'MSI-H-dMMR colorectal cancer cancer' ee lagu daweeyay pembrolizumab aysan arkin kansarkooda inuu ku faafo bartamaha 16.5 bilood, marka loo eego bukaanada lagu daaweeyay kimoterabiga caadiga ah ee arkay burooyinkooda inay koraan bartamihii 8.2 bilood. Bukaannada qaata kiimoteraabiga caadiga ah sidoo kale waxay leeyihiin waxyeelo ka daran kuwa bukaanka qaata pembrolizumab. Natiijooyinka daraasadda oo dhammaystiran ayaa la daabacay gudaha New England Journal of Medicine bishii Diseembar 2, 2020.

Kooxda Istaagista ah ee istaandarka kansarka midab-kala-soocida kansarka waxay wax weyn ku biirisay ikhtiyaarka daaweynta ee la hagaajiyay ee MSI-H-dMMR colorectal bukaanka, ayuu yiri Phillip A. Sharp, PhD, gudoomiyaha guddiga latalinta cilmiga sayniska ee istaag ilaa kansarka bare ka ah Machadka David H. Koch Institute for Integrative Cancer Research ee Massachusetts Institute of Technology. "Tani waa tusaale weyn oo ah sida qaabka wadajirka ah ee cilmibaadhista iskaashi ugu istaago kansarka uu saamayn toos ah ugu leeyahay nolosha bukaannada kansarka."

Kansarka malawadka waa sababta labaad ee ugu badan ee keenta dhimashada kansarka ragga iyo dumarka Ameerikaanka ah ee la isku daray iyo ku dhowaadba 148,000 Americans heli doono baaritaan cusub ee kansarka malawadka ama malawadka sanadka 2020. Halka heerarka dhimashada kansarka mindhicirka malawadka ay aad hoos ugu dhacday sababo la xiriira baaritaanka iyo hagaajinta daaweynta oo kordhay, 1dii qof ee qaangaar ahba mid ayaa da'diisu tahay 3 ama ka weyn ha helin baaritaanka lagu taliyay. Kiisaska cusub ee kansarka malawadka waa ku dhaca heerka sii kordhaya ka mid ah dhalinyarada iyo da 'dhexe ee ku nool Mareykanka, oo leh tirada kiisaska kansarka malawadka dadka ka yar 50 sano ayaa la filayaa inay kudhowaad laba jibbaaraan by 2030.

Maaddaama kansarka mindhicirka mindhicirku uu si aan kala sooc lahayn u saameynayo dadka midabka leh
(Dadka madow waxay leeyihiin heerarka ugu sareeya kansarka mindhicirka mindhicirka ee koox kasta oo jinsi ama qowmiyadeed ah oo ku nool Mareykanka), hagaajinta baaritaanka iyo saxsanaanta cusub iyo daaweynta la bartilmaameedsaday waa inay gaaraan bukaanada oo dhan. SU2C waxay ku dhawaaqday Mashruuca Sinaanta Caafimaadka Janaayo 2020. Hindisahan wuxuu ubaahanyahay dhamaan kooxaha mustaqbalka ee raadinaya maalgalinta istaagida kansarka si wax looga qabto shaqaalaynta iyo sii haysashada bukaanada ka kala yimid kooxaha qowmiyadaha iyo jinsiyadaha kala duwan iyo bulshooyinka aan la hubin si loo wanaajiyo kaqeybgalka kaladuwan ee tijaabooyinka bukaan socodka. Hindisaha waxaa sidoo kale ka mid ah iskaashi lala yeesho kooxaha u doodista iyo warshadaha iyo taageerayaasha shirkadaha si horay loogu socdo dadaalka cilmi baarista iyo wacyigelinta bulshada.

Kooxda Riyada SU2C Colorectal Cancer Team waxaa maamula Iskaashatada sayniska ee istaag ilaa kansarka, Ururka Mareykanka ee Baaritaanka Kansarka.

Source:

U istaag Kansarka

Mirabai Vogt-James
310-739-5576

Tixraaca qoraallada:

Andre, T., et al. (2020) Pembrolizumab oo ku taal Microsatellite-Xasillooni darro – Kansarka Midab-Kala-Baxyada Sare ee Sare. New England Journal of Medicinedoi.org/10.1056/NEJ Moa2017699.

Mozocare waa barxad marin u helid caafimaad oo loogu talagalay isbitaalada iyo bukaan socod eegtada si looga caawiyo bukaan socodka helitaanka daryeelka caafimaad ee ugu fiican qiime jaban.

Faahfaahin dheeraad ah waxaad nagala soo xiriiri kartaa mozo@mozocare.com ama wac + 91-8826883200